Company: Sanofi · Reason for receipt of fees: Analysing in 2003 the results of a study to examine by Sanofi to see if its recommended indications for use of irbesartan in diabetic albuminuria led to over-diagnosis or over-treatment · Total amount received: £2,000 to under £5,000
Other sources of income or benefits from other organisations relevant to medical practice
Company: Applied Nanodetectors Ltd · Reason for receipt of fees: Advice in 2013 about how to assess the diagnostic usefullness of their Nanaodetectors in order to predict the opitimum treatment of patients · Total amount received: £100 to under £1,000
Fees directly received from other medical companies
Company: Oxford University Press · Reason for receipt of fees: Annual royalties from the Oxford Handbook of Clinical Diagnosis · Total amount received: £5,000 to under £10,000
Something wrong with this declaration? Contact team@sunshineuk.org to let them know.